{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T23:20:16Z","timestamp":1790292016517,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2005,12,1]],"date-time":"2005-12-01T00:00:00Z","timestamp":1133395200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1038\/nrd1900","type":"journal-article","created":{"date-parts":[[2005,12,8]],"date-time":"2005-12-08T09:59:54Z","timestamp":1134035994000},"page":"1005-1014","source":"Crossref","is-referenced-by-count":180,"title":["Finding New Tricks For Old Drugs: An Efficient Route For Public-Sector Drug Discovery"],"prefix":"10.1038","volume":"4","author":[{"given":"Kerry A.","family":"O'Connor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan L.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrd1900_CR1","doi-asserted-by":"crossref","unstructured":"International Human Genome Sequencing Consortium. Finishing the euchromatic sequence of the human genome. Nature 431, 931\u2013945 (2004).","DOI":"10.1038\/nature03001"},{"key":"BFnrd1900_CR2","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1126\/science.1091867","volume":"302","author":"E Zerhouni","year":"2003","unstructured":"Zerhouni, E. Medicine. The NIH Roadmap. Science 302, 63\u201372 (2003).","journal-title":"Science"},{"key":"BFnrd1900_CR3","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1126\/science.1105511","volume":"306","author":"CP Austin","year":"2004","unstructured":"Austin, C. P., Brady, L. S., Insel, T. R. & Collins, F. S. NIH Molecular Libraries Initiative. Science 306, 1138\u20131139 (2004).","journal-title":"Science"},{"key":"BFnrd1900_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1126\/science.1090521","volume":"302","author":"G Duyk","year":"2003","unstructured":"Duyk, G. Attrition and translation. Science 302, 603\u2013605 (2003).","journal-title":"Science"},{"key":"BFnrd1900_CR5","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1126\/science.302.5643.218","volume":"302","author":"J Couzin","year":"2003","unstructured":"Couzin, J. Molecular medicine. NIH dives into drug discovery. Science 302, 218\u2013221 (2003).","journal-title":"Science"},{"key":"BFnrd1900_CR6","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1126\/science.1083395","volume":"300","author":"RL Strausberg","year":"2003","unstructured":"Strausberg, R. L. & Schreiber, S. L. From knowing to controlling: a path from genomics to drugs using small molecule probes. Science 300, 294\u2013295 (2003).","journal-title":"Science"},{"key":"BFnrd1900_CR7","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/nrd1347","volume":"3","author":"MD Rawlins","year":"2004","unstructured":"Rawlins, M. D. Cutting the cost of drug development? Nature Rev. Drug Discov. 3, 360\u2013364 (2004).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd1900_CR8","doi-asserted-by":"publisher","first-page":"10543","DOI":"10.1021\/ja035413p","volume":"125","author":"SJ Haggarty","year":"2003","unstructured":"Haggarty, S. J., Clemons, P. A. & Schreiber, S. L. Chemical genomic profiling of biological networks using graph theory and combinations of small molecule perturbations. J. Am. Chem. Soc. 125, 10543\u201310545 (2003).","journal-title":"J. Am. Chem. Soc."},{"key":"BFnrd1900_CR9","doi-asserted-by":"publisher","first-page":"5129","DOI":"10.1074\/jbc.R400030200","volume":"280","author":"BN Armbruster","year":"2005","unstructured":"Armbruster, B. N. & Roth, B. L. Mining the receptorome. J. Biol. Chem. 280, 5129\u20135132 (2005).","journal-title":"J. Biol. Chem."},{"key":"BFnrd1900_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd1346","volume":"3","author":"BL Roth","year":"2004","unstructured":"Roth, B. L., Sheffler, D. J. & Kroeze, W. K. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nature Rev. Drug Discov. 3, 353\u2013359 (2004).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd1900_CR11","doi-asserted-by":"publisher","first-page":"3502","DOI":"10.1128\/JVI.78.7.3502-3513.2004","volume":"78","author":"C Coito","year":"2004","unstructured":"Coito, C., Diamond, D. L., Neddermann, P., Korth, M. J. & Katze, M. G. High-throughput screening of the yeast kinome: identification of human serine\/threonine protein kinases that phosphorylate the hepatitis C virus NS5A protein. J. Virol. 78, 3502\u20133513 (2004).","journal-title":"J. Virol."},{"key":"BFnrd1900_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/nmeth731","volume":"2","author":"SA Johnson","year":"2005","unstructured":"Johnson, S. A. & Hunter, T. Kinomics: methods for deciphering the kinome. Nature Methods 2, 17\u201325 (2005). In references 11 and 12 the approach for screening the 'kinome' is validated.","journal-title":"Nature Methods"},{"key":"BFnrd1900_CR13","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1126\/science.1075762","volume":"298","author":"G Manning","year":"2002","unstructured":"Manning, G., Whyte, D. B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912\u20131934 (2002).","journal-title":"Science"},{"key":"BFnrd1900_CR14","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/nrd892","volume":"1","author":"AL Hopkins","year":"2002","unstructured":"Hopkins, A. L. & Groom, C. R. The druggable genome. Nature Rev. Drug Discov. 1, 727\u2013730 (2002).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd1900_CR15","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"TT Ashburn","year":"2004","unstructured":"Ashburn, T. T. & Thor, K. B. Drug repositioning: identifying and developing new uses for existing drugs. Nature Rev. Drug Discov. 3, 673\u2013683 (2004).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd1900_CR16","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nrd1609","volume":"4","author":"CT Keith","year":"2005","unstructured":"Keith, C. T., Borisy, A. A. & Stockwell, B. R. Multicomponent therapeutics for networked systems. Nature Rev. Drug Discov. 4, 71\u201378 (2005).","journal-title":"Nature Rev. Drug Discov."},{"key":"BFnrd1900_CR17","unstructured":"Pharmaceutical Researcher Manufacturers of America. Pharmaceutical Industry Profile 2005 [online], < http:\/\/www.phrma.org\/publications\/publications\/17.03.2005.1142.cfm > (2005)."},{"key":"BFnrd1900_CR18","doi-asserted-by":"publisher","first-page":"432","DOI":"10.3201\/eid0904.020268","volume":"9","author":"LF McCaig","year":"2003","unstructured":"McCaig, L. F., Besser, R. E. & Hughes, J. M. Antimicrobial drug prescription in ambulatory care settings, United States, 1992\u20132000. Emerging Infect. Dis. 9, 432\u2013437 (2003).","journal-title":"Emerging Infect. Dis."},{"key":"BFnrd1900_CR19","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/nature03180","volume":"433","author":"JD Rothstein","year":"2005","unstructured":"Rothstein, J. D. et al. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433, 73\u201377 (2005). A pivotal paper in which cleverly designed phenotypic screens are used to identify a promising treatment strategy for a serious disease involving drugs already approved for human use.","journal-title":"Nature"},{"key":"BFnrd1900_CR20","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0896-6273(00)80086-0","volume":"16","author":"JD Rothstein","year":"1996","unstructured":"Rothstein, J. D. et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16, 675\u2013686 (1996).","journal-title":"Neuron"},{"key":"BFnrd1900_CR21","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1002\/ana.20003","volume":"55","author":"NJ Maragakis","year":"2004","unstructured":"Maragakis, N. J., Dykes-Hoberg, M. & Rothstein, J. D. Altered expression of the glutamate transporter EAAT2b in neurological disease. Ann. Neurol. 55, 469\u2013477 (2004).","journal-title":"Ann. Neurol."},{"key":"BFnrd1900_CR22","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1126\/science.308.5722.632b","volume":"308","author":"E Beghi","year":"2005","unstructured":"Beghi, E., Bendotti, C. & Mennini, T. Merits of a new drug trial for ALS? Science 308, 632\u2013633; author reply 632\u2013633 (2005).","journal-title":"Science"},{"key":"BFnrd1900_CR23","first-page":"146","volume":"49","author":"P Couratier","year":"1994","unstructured":"Couratier, P., Vallat, J. M., Merle, L., Preux, P. M. & Hugon, J. Report of six sporadic cases of ALS patients receiving ceftriaxone. Therapie 49, 146 (1994).","journal-title":"Therapie"},{"key":"BFnrd1900_CR24","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/BF02343499","volume":"15","author":"V Carelli","year":"1994","unstructured":"Carelli, V., Liguori, R., Cordivari, C., Bianchedi, G. & Montagna, P. Ceftriaxone is ineffective in ALS. Ital. J. Neurol. Sci. 15, 66 (1994).","journal-title":"Ital. J. Neurol. Sci."},{"key":"BFnrd1900_CR25","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/00019052-200406000-00019","volume":"17","author":"IJ Koralnik","year":"2004","unstructured":"Koralnik, I. J. New insights into progressive multifocal leukoencephalopathy. Curr. Opin. Neurol. 17, 365\u2013370 (2004).","journal-title":"Curr. Opin. Neurol."},{"key":"BFnrd1900_CR26","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s00115-005-1900-2","volume":"76","author":"B Schreiner","year":"2005","unstructured":"Schreiner, B., Kieseier, B. C., Hartung, H. P., Hohlfeld, R. & Wiendl, H. Blocking adhesion molecules with natalizumab in multiple sclerosis. Nervenarzt 76, 999\u20131005 (2005).","journal-title":"Nervenarzt"},{"key":"BFnrd1900_CR27","first-page":"S108","volume":"22","author":"AK Imperato","year":"2004","unstructured":"Imperato, A. K., Bingham, C. O. & Abramson, S. B. Overview of benefit\/risk of biological agents. Clin. Exp. Rheumatol. 22, S108\u2013S114 (2004).","journal-title":"Clin. Exp. Rheumatol."},{"key":"BFnrd1900_CR28","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1126\/science.1103492","volume":"306","author":"GF Elphick","year":"2004","unstructured":"Elphick, G. F. et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 306, 1380\u20131383 (2004). In this paper, the authors use a combination of phenotypic and molecular-target-based screening approaches to identify the co-receptor for JC virus, the causative agent of PML.","journal-title":"Science"},{"key":"BFnrd1900_CR29","doi-asserted-by":"publisher","first-page":"8269","DOI":"10.1074\/jbc.M006968200","volume":"276","author":"A Bhatnagar","year":"2001","unstructured":"Bhatnagar, A. et al. The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis. J. Biol. Chem. 276, 8269\u20138277 (2001).","journal-title":"J. Biol. Chem."},{"key":"BFnrd1900_CR30","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1177\/095646249200300409","volume":"3","author":"CD Summerbell","year":"1992","unstructured":"Summerbell, C. D., Youle, M., McDonald, V., Catalan, J. & Gazzard, B. G. Megestrol acetate versus cyproheptadine in the treatment of weight loss associated with HIV infection. Int. J. STD AIDS 3, 278\u2013280 (1992).","journal-title":"Int. J. STD AIDS"},{"key":"BFnrd1900_CR31","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1126\/science.306.5695.384","volume":"306","author":"J Couzin","year":"2004","unstructured":"Couzin, J. Drug safety. Withdrawal of Vioxx casts a shadow over COX-2 inhibitors. Science 306, 384\u2013385 (2004).","journal-title":"Science"},{"key":"BFnrd1900_CR32","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1056\/NEJM199708283370901","volume":"337","author":"HM Connolly","year":"1997","unstructured":"Connolly, H. M. et al. Valvular heart disease associated with fenfluramine-phentermine. N. Engl. J. Med. 337, 581\u2013588 (1997).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd1900_CR33","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJM199809103391109","volume":"339","author":"RB Devereux","year":"1998","unstructured":"Devereux, R. B. Appetite suppressants and valvular heart disease. N. Engl. J. Med. 339, 765\u2013766 (1998).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd1900_CR34","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1161\/01.CIR.102.23.2836","volume":"102","author":"RB Rothman","year":"2000","unstructured":"Rothman, R. B. et al. Evidence for possible involvement of 5-HT2B receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 102, 2836\u20132841 (2000).","journal-title":"Circulation"},{"key":"BFnrd1900_CR35","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1124\/mol.63.6.1223","volume":"63","author":"V Setola","year":"2003","unstructured":"Setola, V. et al. 3,4-Methylenedioxymethamphetamine (MDMA, \u201cEcstasy\u201d) induces fenfluramine-like proliferative actions on human cardiac valvular interstitial cells in vitro. Mol. Pharmacol. 63, 1223\u20131229 (2003).","journal-title":"Mol. Pharmacol."},{"key":"BFnrd1900_CR36","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0026-895X(24)26444-0","volume":"57","author":"LW Fitzgerald","year":"2000","unstructured":"Fitzgerald, L. W. et al. Possible role of valvular serotonin 5-HT2B receptors in the cardiopathy associated with fenfluramine. Mol. Pharmacol. 57, 75\u201381 (2000).","journal-title":"Mol. Pharmacol."},{"key":"BFnrd1900_CR37","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1038\/nm764","volume":"8","author":"JM Launay","year":"2002","unstructured":"Launay, J. M. et al. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nature Med. 8, 1129\u20131135 (2002).","journal-title":"Nature Med."},{"key":"BFnrd1900_CR38","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1124\/jpet.102.039883","volume":"303","author":"A Newman-Tancredi","year":"2002","unstructured":"Newman-Tancredi, A. et al. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT1 and 5-HT2, receptor subtypes. J. Pharmacol. Exp. Ther. 303, 815\u2013822 (2002).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"BFnrd1900_CR39","doi-asserted-by":"publisher","first-page":"730","DOI":"10.4065\/78.6.730","volume":"78","author":"CM Flowers","year":"2003","unstructured":"Flowers, C. M., Racoosin, J. A., Lu, S. L. & Beitz, J. G. The US Food and Drug Administration's registry of patients with pergolide-associated valvular heart disease. Mayo Clin. Proc. 78, 730\u2013731 (2003).","journal-title":"Mayo Clin. Proc."},{"key":"BFnrd1900_CR40","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1016\/S0140-6736(04)15945-X","volume":"363","author":"G Van Camp","year":"2004","unstructured":"Van Camp, G. et al. Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart disease. Lancet 363, 1179\u20131183 (2004).","journal-title":"Lancet"},{"key":"BFnrd1900_CR41","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1002\/mds.20201","volume":"19","author":"J Horvath","year":"2004","unstructured":"Horvath, J. et al. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov. Disord. 19, 656\u2013662 (2004).","journal-title":"Mov. Disord."},{"key":"BFnrd1900_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/BF00432813","volume":"55","author":"BV Clineschmidt","year":"1977","unstructured":"Clineschmidt, B. V., Hanson, H. M., Pflueger, A. B. & McGuffin, J. C. Anorexigenic and ancillary actions of MK-212 (6-chloro-2-(1-piperazinyl)-pyrazine; CPP). Psychopharmacology (Berl.) 55, 27\u201333 (1977).","journal-title":"Psychopharmacology (Berl.)"},{"key":"BFnrd1900_CR43","doi-asserted-by":"publisher","first-page":"S449","DOI":"10.1002\/j.1550-8528.1995.tb00212.x","volume":"3","author":"CT Dourish","year":"1995","unstructured":"Dourish, C. T. Multiple serotonin receptors: opportunities for new treatments for obesity? Obes. Res. 3, S449\u2013S462 (1995).","journal-title":"Obes. Res."},{"key":"BFnrd1900_CR44","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/s002130050952","volume":"143","author":"SP Vickers","year":"1999","unstructured":"Vickers, S. P., Clifton, P. G., Dourish, C. T. & Tecott, L. H. Reduced satiating effect of d-fenfluramine in serotonin 5-HT2C receptor mutant mice. Psychopharmacology (Berl.) 143, 309\u2013314 (1999).","journal-title":"Psychopharmacology (Berl.)"},{"key":"BFnrd1900_CR45","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1517\/14728222.5.6.685","volume":"5","author":"BL Roth","year":"2001","unstructured":"Roth, B. L. & Shapiro, D. A. Insights into the structure and function of 5-HT2 family serotonin receptors reveal novel strategies for therapeutic target development. Exp. Opin. Ther. Targets 5, 685\u2013695 (2001).","journal-title":"Exp. Opin. Ther. Targets"},{"key":"BFnrd1900_CR46","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1016\/S0197-0186(01)00052-3","volume":"39","author":"CK Combs","year":"2001","unstructured":"Combs, C. K., Bates, P., Karlo, J. C. & Landreth, G. E. Regulation of \u03b2-amyloid stimulated proinflammatory responses by peroxisome proliferator-activated receptor alpha. Neurochem. Int. 39, 449\u2013457 (2001).","journal-title":"Neurochem. Int."},{"key":"BFnrd1900_CR47","doi-asserted-by":"publisher","first-page":"7504","DOI":"10.1523\/JNEUROSCI.23-20-07504.2003","volume":"23","author":"Q Yan","year":"2003","unstructured":"Yan, Q. et al. Anti-inflammatory drug therapy alters b-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci. 23, 7504\u20137509 (2003).","journal-title":"J. Neurosci."},{"key":"BFnrd1900_CR48","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/nm1235","volume":"11","author":"T Kukar","year":"2005","unstructured":"Kukar, T. et al. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Ab42 production. Nature Med. 11, 545\u2013550 (2005).","journal-title":"Nature Med."},{"key":"BFnrd1900_CR49","volume-title":"Genet. Eng. News 24 [online]","author":"V Glaser","year":"2004","unstructured":"Glaser, V. Immune Control pursues seotonin antagonists. Genet. Eng. News 24 [online], < http:\/\/www.immunecontrol.com\/icigen.pdf > (2004)."},{"key":"BFnrd1900_CR50","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00213-004-2017-1","volume":"178","author":"MA Davies","year":"2005","unstructured":"Davies, M. A., Compton-Toth, B. A., Hufeisen, S. J., Meltzer, H. Y. & Roth, B. L. The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine's actions? Psychopharmacology (Berl.) 178, 451\u2013460 (2005).","journal-title":"Psychopharmacology (Berl.)"},{"key":"BFnrd1900_CR51","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0002-9440(10)63132-X","volume":"164","author":"S Eash","year":"2004","unstructured":"Eash, S. et al. Differential distribution of the JC virus receptor-type sialic acid in normal human tissues. Am. J. Pathol. 164, 419\u2013428 (2004).","journal-title":"Am. J. Pathol."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrd1900.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd1900","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd1900.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T09:55:15Z","timestamp":1736157315000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrd1900"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":51,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["BFnrd1900"],"URL":"https:\/\/doi.org\/10.1038\/nrd1900","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}